Page Top

血液・腫瘍内科

  • 診療内容
  • 取り扱っている主な疾患
  • 症例数
  • 手術実績
  • 診療担当医表
  • スタッフ紹介

診療内容

亀田総合病院の血液・腫瘍内科は1990年より開設されました。この間房総半島における白血病、悪性リンパ腫や骨髄腫の治療の中心施設として多くの患者さまの治療に当たってきております。現在では常時70-90名前後の患者さまが入院されており本邦でももっとも大きな血液疾患の治療施設の一つとなっております。さらに当科は日本血液学会の専門医研修施設、日本骨髄バンク認定非血縁者間骨髄移植および骨髄採取指定施設、日本臍血バンク認定臍帯血移植施設として千葉県の血液疾患治療の中心的な施設となっており近年では房総半島、千葉県だけでなく都内やそれ以外の地方からの患者さまも増加してきています。

病棟での診療はシニアレジデント以上のスタッフ6名に加えジュニアレジデント1〜2名の医師で患者さまの治療を担当しております。特に骨髄移植、末梢血幹細胞移植などを用いた治療では、既に多くの経験と実績を上げております。骨髄移植は1990年から開始されこれまでに同種幹細胞移植の試行数は400例を超しております。最近の3年間の移植数は年間15例前後となっています。また悪性リンパ腫や多発性骨髄腫に対する自家末梢血幹細胞移植も積極的に行っており、これまでのべ300例を超える自家移植が行われております。これらを行う施設としては以前からのKタワー9階に無菌室16床を含む36床、また新しく出来たAタワー8階に個室2棟を含む42床が常時フル稼働しています。

亀田総合病院では、どの患者さまにも最新鋭の機器による最新の治療を行えるように努力しております。たとえば画像診断の分野では、どの科においてもPETをはじめ、MRI、CTなどによる画像診断検査が緊急な場合を含めて必要に応じて行える体勢がとられております。この事は急変する病態が多い血液悪性腫瘍の患者さまにとってはきわめて重要なであり、高度医療を行う上で必須であると考えられます。

臨床検査センターにはFACSが導入され、30種類を越えるモノクローナル抗体を用いた白血病・リンパ腫, 骨髄腫の表面抗原の解析診断がルーチンに行われ、様々の造血器悪性腫瘍のモノクローナル抗体による診断が迅速に行える体制がとられております。特に骨髄腫の治療経過を判定する上での骨髄微少残存病変(MRD)の検索は8-10カラーフロサイトメトリーを用いてルーチンに行われ国内をリードしています。また、再生不良性貧血、骨髄異形性症候群ではPNH赤血球の高感度測定法による測定をおこない、免疫抑制療法が有効と思われる再不貧やMDSのサブグループの診断が行われております。特にリンパ腫の診断では血液検査室、病理部門との協力によりリンパ節生検が行われてから3日以内で表面マーカの解析とH-E標本ができる体制がとられ急速に進行する造血器悪性腫瘍にたいして的確な診断と治療が行われる体制をとっています。病理診断に関しても国内でも有数の血液病理専門医が隔週で来院し病理診断をより確かなものとしています。またFISHやPCRを用いての遺伝子診断も多くの疾患でルーチンに行われ正確な診断を基に国内的にはもちろん国際的にも最新の診断と治療が行われています。

造血幹細胞移植は当科でも力をいれている分野の一つですが、先に述べましたように年間30-40例前後の臍帯血、同種および自家末梢血幹細胞、同種骨髄移植をおこなっています。当科の特徴としては地域性を反映して高齢者での移植が多いことです。特に骨髄腫では70才以上の患者さんに対しても、可能な患者さんには自家末梢血幹細胞移植を積極的に行い良好な成績が得られております。また、白血病や悪性度の高いリンパ腫に対してわれわれは60才以上の患者さまに対しても同種幹細胞移植を積極的におこなっており、60才以下の患者さまと遜色ない良好な成績が上げられています。またいくつもの臓器障害を有したり、治療抵抗性であったりする難治例での移植にも積極的に取り組んでいますがその治療成績はまだ十分とは言いがたく、今後はこれらの患者さまの治療成績の向上が課題と思われます。これらの重症の患者さまの移植を安全かつ効果的に行うために、GVH病のコントロールに必要なサイクロスポリン、タクロリムスの血中濃度の緊急測定、真菌感染におけるアスペルギルス抗原の院内測定といった新しい治療に必要な検査のサポートが受けられる体制がとられております。輸血部では血液細胞の分離保存専用のクリーンベンチを始め、血液照射装置、血液成分分離装置、-135℃の超低温冷蔵庫2台などが備えられ、造血細胞のプロセッシングと保存が行われており最先端の血液疾患の診断と治療に対応できます。放射線部ではライナックが備えられ、CTやMRI、PETなどの最先端の診断機械なども多く備えられています。


学会活動としては、日本血液学会、リンパ網内系学会、日本造血幹細胞学会、American Society of Blood and Marrow Transplantation、European Haematology Association, American Society of Hematologyなどの国内外の学会に積極的に参加・発表しております。当科より発信された主な業績としては、ミカファンギンのよるトリコスポロン症のbreak through (Clin Infec Dis. 2006)血管内大細胞型B細胞リンパ腫の診断とランダム皮膚生検の有効性(Mayo Clin Proc. 2007), 幹細胞移植患者やリツキシマブ投与患者におけるB型肝炎の再活性化(Cancer. 2010)、血管内リンパ腫とNeurolymphomatosis との関連 (Cancer 2011), イマチニブ服用患者におけるα2プラスミン活性の低下と粘膜出血 (Thromb Haemost 2009)、腎不全をともなった骨髄腫の患者の腎機能回復と尿中アルブミンとの関連(Blood Cancer J. 2014), MDSや骨髄腫におけるmultidetector CT による予後予測(Leukemia. 2018, Blood Advances 2018) , 骨髄腫患者に対するdaratumumab投与とregulatory T-cell (Haematologica 2019), ランダム皮膚生検の感度と特異度(Br J Dermatol. 2019, Blood 2019, Brit J Haematol 2019) など多岐にわたっています。その他にも当院の特徴である電子カルテシステムを利用した質の高い臨床研究を立案し、積極的に行うことで今後とも当院から有用な情報を世界に発信できるように努力してゆきたいと考えております。

このようにすぐれた設備、医療環境のもとで私たちは国の内外をリードする創造的な血液・腫瘍内科を目標に、最新の知見に基づいた診断や治療をおこない、患者さまやそのご家族に満足して頂ける医療を目指して共に今後も努力してゆきたいと考えております。


 
論文業績 (過去5年) (共同研究は*)
2021年 ▼2020年 ▼2019年 ▼2018年 ▼2017年

2021年

1) Tsushima T, Suzuki T, Terao T, Miura D, Narita K, Takeuchi M, Shimuzu A, Matsue K.  Light chain deposition disease involving kidney and liver in a patient with IgD myeloma. BMC Nephrol. 2021 Jan 23;22(1):40. doi: 10.1186/s12882-021-02246-9.PMID: 33485303
 

2) Terao T, Machida Y, Narita K, Kuzume A, Tabata R, Tsushima T, Miura D, Takeuchi M, Tateishi U, Matsue K. Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma.  Eur Radiol. 2021 Jan 26. Doi:10.1007 /s00330-021-07687-2.  Online ahead of print
 

3) Terao T, Matsue K  Bone Marrow Necrosis in Acute Monoblastic Leukemia. N Engl J Med. 2021 Feb 18;384(7):650. doi: 10.1056/NEJMicm2026508  PMID: 33596359
 

4) Terao T, Tsushima T, Fukumoto A, Kuzume A, Miura D, Narita K, Takeuchi M, Matsue K. EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide. Int J Hematol. 2021 Mar 6. doi: 10.1007/s12185-021-03111-z. Online ahead of print
 

5) Kuzume A, Tabata R, Terao T, Tsushima T, Miura D, Narita K, Takeuchi M, Matsue K.
 Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure.
Br J Haematol. 2021 Mar 21. doi: 10.1111/bjh.17412. Online ahead of print
 

6) Toshiki Terao, Ken-ichi Matsuoka, Kentaro Narita, Takafumi Tsushima, Satoshi Yuyama, Ayumi Kuzume, Rikako Tabata, Daisuke Miura, Masami Takeuchi, Kosei Matsue. Letermovir administration to prevent cytomegalovirus reactivation is the potential risk of chronic graft-versus-host disease in patients who received haploidentical stem-cell transplantation with post-transplant cyclophosphamide. Front. Oncol., 29 April 2021
 

7) Yoroidaka T, Narita K, Takamatsu H, Fujisawa M, Nakao S, Matsue K. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods. Sci Rep. 2021 May 27;11(1):11218. doi: 10.1038/s41598-021-89761-9
 

8) Toshiki Terao1, Kenji Hirata2, Youichi Machida3, Ayumi Kuzume1, Rikako Tabata1, Takafumi Tsushima1, Daisuke Miura1, Kentaro Narita1,Masami Takeuchi1, Ukihide Tateishi4, and Kosei Matsue. Metabolic heterogeneity based on SUVmax in pretreatment 18F-FDG PET/CT showed worse prognosis in patients with newly diagnosed multiple myeloma. Clin Nucl Med 2021 Jun 25. doi: 10.1097/RLU.0000000000003773. Online ahead of print.PMID: 34172600
 

9) Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, Rodriguez-Otero P, Powles R, Matsue K, Shah N, Anderson LD Jr, Streetly M, Wilson K, Le HV, Swern AS, Agarwal A, Siegel DS.  KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021 Jun 18;11(6):116. doi: 10.1038/s41408-021-00507-2.


 
2020年

1)*Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T. Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Combined With High-Dose Methotrexate Plus Intrathecal Chemotherapy for Newly Diagnosed Intravascular Large B-cell Lymphoma (PRIMEUR-IVL): A Multicentre, Single-Arm, Phase 2 Trial. Lancet Oncol 2020; 21 (4): 593-602.
 

2)Terao T, Machida Y, Tsushima T, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K. Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice. Br J Haematol. 2020 Apr 6. doi: 10.1111/bjh.16633. Online ahead of print.
 

3)*Sunami K, Matsue K, Suzuki K, Takezako N, Shinagawa A, Sakurai S, Tamakoshi H, Biyukov T, Peluso T, Richardson P. Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. Cancer Sci. 2020 Apr 16. doi: 10.1111/cas.14415. Online ahead of print.
 

4)Kobayashi H, Terao T, Tsushima T, Abe Y, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K. Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma. Cancer Med. 2020 Apr 20. doi: 10.1002/cam4.3050. Online ahead of print.
 

5)Terao T, Narita K, Tsushima T, Miura D, Takeuchi M, Matsue K. Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases. Leuk Lymphoma. 2020 Apr 23:1-3. doi: 10.1080/10428194.2020.1742904. Online ahead of print
 

6)*Suzuki Y, Kohno K, Matsue K, Sakakibara A, Ishikawa E, Shimada S, Shimada K, Mabuchi S, Takahara T, Kato S, Nakamura S, Satou A. PD-L1 (SP142) Expression in Neoplastic Cells Predicts a Poor Prognosis for Patients With Intravascular Large B-cell Lymphoma Treated With Rituximab-Based Multi-Agent Chemotherapy. Cancer Med 2020 May 5. doi: 10.1002/cam4.3104. Online ahead of print
 

7)Terao, T Tsushima, D Miura, K Narita, M Takeuchi, K Matsue . Social frailty predicts worse outcomes in patients with multiple myeloma: A novelty in an old  T eJHaem
 

8)Kitadate A, Narita K, Fukumoto K, Terao T, Tsushima T, Kobayashi H, Abe Y, Miura D, Takeuchi M, Machida Y, Matsue K. Baseline total lesion glycolysis combined with interim positron emission tomography‐computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma. Cancer Med. 2020 Aug;9(15):5509-5518. doi: 10.1002/cam4.3226. Epub 2020 Jun 18.
 

9)K Narita, H Kobayashi, T Suzuki, D Ichikawa, K Yamazaki, H Terawaki, Light chain deposition disease in a patient with MYD88 L265P mutation-positive low-grade B-cell … Clinical Lymphoma Myeloma and Leukemia, 2020 Nov;20(11):e805-e808.
 

10) Trearo T, Tsushima T, Miura D, Narita K, Takeuchi M, Matsue K. Social frailty predicts worse outcomes in patients with multiple myeloma: A novelty in an old approach. eJHaem 2020 ;1(1): 281-285
 

11)Matsue K, Abe Y, Narita K, Kobayashi H, Kitradate A, Miura D, Takeuchi M, Takeuchi K. Bone marrow infiltration pattern in patients with intravascular large B‐cell lymphoma diagnosed by random skin biopsy. eJHaem 2020 ;1(1): 281-285
 

12)Kaji D, Ota Y, Sato Y, Nagafuji K, Ueda Y, Okamoto M, Terasaki Y, Tsuyama N, Matsue K, Kinoshita T, Yamamoto G, Taniguchi S, Chiba S, Ohshima K, Izutsu K,. Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. Blood adv. 2020 Sep 22;4(18):4442-4450.
 

13)Enzan N, Kitadate A, Suzuki H, Yoshioka M, Narita K, Tanaka A, Matsue K. Intravascular large B-cell lymphoma diagnosed by incisional random skin biopsy after failure of diagnosis using punch biopsy: A case report. J Cutan Pathol. 2020 Sep 17. doi: 10.1111/cup.13877. Online ahead of print
 

14)Terao T, Ashimine H, Tsuyama N, Ikeda D, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Takeuchi K, Matsue K. Development of BCR-ABL1-positive ɤδ T-cell leukemia after treatment for thymoma type B1. Leuk Lymphoma. 2020 Dec 7:1-6
 

15)Kuzume A, Terao T, Miura D, Takeuchi K, Matsue K. Tiger man sign in sarcoid myopathy.
Rheumatology (Oxford). 2020 Dec 25:keaa833. doi: 10.1093/rheumatology/keaa833. Online ahead of print



2019年
1) Abe Y, Sunami K, Yamashita T, Ueda U, Takamatsu H, Narita K, Kobayashi H, Kitadate A, Takeuchi M, and Matsue K. Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society. Oncotarget 2019;10(5): 595-605.

2) Kobayashi H, Abe Y, Miura M, Narita K, Kitadate A, Takeuchi M, and Matsue K. Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis. Int J Hematol. 2019 Mar;109(3):286-291

3) Kobayashi H, Abe Y, Narita K, Kitadate A, Takeuchi M, and Matsue K. Prevalence and clinical implications of t(11;14) in patients with amyloid light chain-amyloidosis with or without concurrent multiple myeloma. Jpn J Clin Oncol. 2019 Feb 1;49(2):195-198.

4) Enzan N, Kitadate A, Tanaka A, Matsue K. Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma: A clinicopathological study of 25 patients. Br J Dermatol. 2019 Jan 4. doi: 10.1111/bjd.17603. [Epub ahead of print]

5) Matsue K, Abe Y, A, Kitadate A, Miura D, Narita K, Kobayashi H, Takeuchi M, Enzan N, Tanaka N, and Takeuchi K. Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Blood. 2019 Mar 14;133(11): 1257-1259.

6) Abe Y, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K. Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2019 Jan 28. doi: 10.1007/s 00259-019-4275-5. [Epub ahead of print]

7) Abe Y, Kitadate A, Usui Y, Narita K, Kobayashi H, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K. Diagnostic and Prognostic Value of Using 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Peripheral T-cell Lymphoma. Clin Nucl Med. 2019 May;44(5):e336-e341. 

8) Abe Y, Kobayashi T, Usui Y, Narita K, Kobayashi H, Kitadate A, Miura M, Takeuchi M, and Matsue K.  N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma. Oncotarget. 2019 Feb 1;10(10):1160-1170.

9) *Takamatsu H, Yoroidaka T, Fujisawa M, Kobori K, Hanawa M, Yamashita T, Murata R, Ueda M, Nakao S, Matsue K. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol. 2019 Apr;109(4):505. doi: 10.1007/s12185-019-02621-1

10) Abe Y, Ikeda S, Kitadate A,, Narita K, Kobayashi H, Miura D, Takeuchi M, O’uchi E, O’uchi T, Matsue K. Low hexokinase-2 expression-associated false-negative ¹⁸F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019 46(6):1345-1350.

11) Kobayashi H, Tsushima T, Terao T, Abe Y, Miura M, Narita K, Kitadate A, Takeuchi M, Matsue K. Evaluation [A1] of the safety and efficacy of daratumumab outside of clinical trials. Int J Hematol. 2019 Apr 8. doi: 10.1007/s12185-019-02648-4. [Epub ahead of print]

12) Kitadate A, Kobayashi K, Abe A, Kentaro K, Miura D, Takeuchi M, and Matsue M. Pretreatment CD38-positive regulatory T-cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma. Haematologica. 2019 Apr 19. pii: haematol.2019.219683. doi: 10.3324/haematol. 2019.219683. [Epub ahead of print]

13) Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Ouchi E, Ouchi T, Matsue K. Medullary abnormalities in the appendicular skeletons detected by ¹⁸F-FDG PET/CT predict an unfavorable prognosis in newly diagnosed multiple myeloma patients with established high-risk factors. AJR Am J Roentgenol. 2019 Jun 19:1-7. doi: 10.2214/ AJR.19.21283. [Epub ahead of print]

14) Abe Y, Kobayashi T, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, and Matsue K. Left ventricular diastolic function assessment using echocardiography for predicting carfilzomib-induced cardiovascular events in relapsed/refractory myeloma. Blood Advances. 2019 Jun 11;3(11):1725-1728. doi: 10.1182/bloodadvances. 2019000247. 

15) Matsue K, Abe Y, Narita K, Kobayashi H, KitadateA, Takeuchi M, Miura D, Takeuchi K. Diagnosis of intravascular large B-cell lymphoma: Novel insights into clinincopathologic features from 42 patients at a single institution over 20-years. Brit J Haematol.  In press.

16) Yoshiaki Abe, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Daisuke Miura, Masami Takeuchi, and Kosei Matsue. High frequency of false-positive serum galactomannan tests among older subjects and the association with elevated serum immunoglobulin G levels. Mycoses 2019 Jun 5. doi: 10.1111/myc.12951. [Epub ahead of print]

17) Narita K, Kobayashi H, Kitadate A, Abe Y, Miura D, Takeuchi M, Matsue K. Neurolymphomatosis of the sciatic and tibial nerves as an initial presentation of lung diffuse large B cell lymphoma detected by positron emission tomography/computed tomography. Int J Hematol. 2019 Jul 15. doi: 10.1007/s12185-019-02705-y. [Epub ahead of print]

18) Terao T, Matsue K. Osteosclerotic myeloma without features of POEMS syndrome. Int J Hematol. 2019 Aug 12. doi: 10.1007/s12185-019-02718-7. [Epub ahead of print]

19)* Takahashi T, Usuki K, Matsue K, Ohno H, Sakura T, Imanaka R, Murakami M, Ohwada S, Takagi T, Sakajiri S. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. Int J Hematol. 2019 Dec;110(6):665-674. doi: 10.1007/s12185-019-02727-6. Epub 2019 Aug 31.

20)* Nakamura A, Ohwada C, Takeuchi M, Takeda Y, Tsukamoto S, Mimura N, Nagisa OH, Sugita Y, Tanaka H, Wakita H, Aotsuka N, Matsue K, Yokote K, Ohara O, Nakaseko C, Sakaida E. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. PLoS One. 2019 Sep 4;14(9):e0221941.

21) Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Matsue K. 18F-FDG PET/CT-Guided Diagnosis and Evaluation of Treatment Response to Cyclosporine A in Maldistributed Subcutaneous Panniculitis-like T-Cell Lymphoma Without Typical Skin Rash. Clin Nucl Med. 2020 Feb;45(2):e69-e71.

22) Enzan N, Kitadate A, Yoshioka M, Narita K, Tanaka A, Matsue K. Cutaneous involvement of diffuse large B-cell lymphoma incidentally diagnosed based on random skin biopsy of normal-appearing skin. Eur J Dermatol. 2019 Dec 1;29(6):666-667

23) *Taneda S, Honda K, Horita S, Matsue K, Usui Y, Mitobe M, Ogura S, Nitta K, Oda H. An Unusual Case of Lysosomal Paraprotein Accumulation in Glomerular Endothelial Cells. Kidney Int Rep. 2019 Oct 1;5(1):109-115.


2018年
1)*Miyamoto T, Nagafuji K, Fujisaki T, Uchida N, Matsue K, Henzan H, Ogawa R, Takase K, Aoki T, Hidaka M, Teshima T, Taniguchi S, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT). Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission. Int J Hematol. 2018;107(4):468-477. 

2)* Takamatsu H, Wee RK, Zaimoku Y, Murata R, Zheng J, Moorhead M, Carlton VEH, Kong KA, Takezako N, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S. A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. Br J Haematol. 2017 Dec 22. doi: 10.1111/bjh.15002. [Epub ahead of print] No abstract available.

4)* Kitadate A, Ikeda S, Abe F, Takahashi N, Shimizu N, Matsue K, Tagawa H. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas. Haematologica. 2018 Jan;103(1):126-135.

5)* Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML and Shimousa Hematology Study Groups. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018 Jan;109(1):182-192. 

6)* Suehara Y, Sakata-Yanagimoto M, Hattori K, Nanmoku T, Itoh T, Kaji D, Yamamoto G, Abe Y, Narita K, Takeuchi M, Matsue K, Sato T, Noguchi M, Baba N, Sakamoto T, Kusakabe M, Kurita N, Kato T, Yokoyama Y, Nishikii H, Obara N, Hasegawa Y, Chiba S. Liquid biopsy for the idenitification of intravascular large B-cell lymphoma. Haematologica. 2018 Jun;103(6):e241-e244.

7)* Tanzima Nuhat S, Sakata-Yanagimoto M, Komori D, Hattori K, Suehara Y, Fukumoto K, Fujisawa M, Kusakabe M, Matsue K, Wakamatsu H, Shimadzu M, Chiba S. Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. Cancer Sci. 2018 Mar 1. doi: 10.1111/cas.13557. [Epub ahead of print]

8)* Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, Komori D, Gershon P, Kiryu M, Tanzima S, Fukumoto K, Enami T, Muratani M, Yoshida K, Ogawa S, Matsue K, Nakamura N, Takeuchi K, Izutsu K, Fujimoto K, Teshima T, Miyoshi H, Gaulard P, Ohshima K, Chiba S.  Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia. 2018 Mar;32(3):694-702. doi: 10.1038/leu.2017.273. Epub 2017 Aug 23.

9) Abe Y, Ugai T, Fujisawa M, Matsue Y, Narita K, Takeuchi M, Matsue K. Prognostic implication of appendicular skeleton bone marrow abnormalities detected using low-dose multidetector computed tomography in patients with myelodysplastic syndrome. Leukemia. 2018 Sep;32(9):2069-2073.

10) Matsue K, Kobayashi H, Matsue Y, Abe Y, Narita K, Kitadate A, Takeuchi M. Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma. Blood Advance 2018 May 8;2(9):1032-1039

11) Narita K, Kobayashi H, Abe Y, Kitadate A, Takeuchi M, Matsue K. Quantification of Bone Marrow Plasma Cell Levels Using Various International Myeloma Working Group Response Criteria in Patients with Multiple Myeloma. Int J Hematol. 2018 Oct;108(4):371-374. 

12)* Maeda A, Nishida Y, Weetall M, Cao L, Branstrom A, Ishizawa J, Nii T, Schober WD, Abe Y, Matsue K, Yoshimura M, Kimura S, Kojima K.  Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma. Oncotarget. 2018 Jun 19;9(47):28547-28560.

13) Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K. Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study. Int J Hematol. 2018 Nov;108(5):524-534.

14) Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Kikuchi Y, Ouchi T, Takeuchi K, Matsue K. Clinical value of abnormal findings on brain magnetic resonance imaging in patients with intravascular large B-cell lymphoma.  Ann Hematol. 2018 Dec;97(12):2345-2352.

15) Abe Y, Usui Y, Narita K, Takeuchi M, Matsue K. Concomitant subcutaneous intravascular lymphoma lesions in a patient with cardiac diffuse large B-cell lymphoma: is intravascular lymphoma a distinct clinical entity?  Int J Hematol. 2018;108(6): 637-639.
 


2017年
1) Matsue K, Matsue Y, Kumata K, Usui Y, Suehara Y, Fukumoto K, Manabu Fujisawa1, Narita K Takeuchi M. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry. Hematol Oncol. 2017;35(3):323-328. PMID: 27140172

2) Suehara Y, Takamatsu H, Fukumoto K, Fujisawa M, Narita K, Usui Y, Takeuchi M, Endean K, Matsue K. Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma. Cancer Science 2017; 108:187-192.

3)* Suzuki K, Sunami K, Ohashi K, Iida S, Mori T, Handa H, Matsue K, Miyoshi M, Bleickardt E, Matsumoto M, Taniwaki M. Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis. Blood Cancer J. 2017 Mar10;7(3):e540

4)* Ri M, Matsue K, Sunami K, Shimazaki C, Hayashi A, Sunaga Y, Sasaki T, Suzuki K. Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma. Int J Hematol. 2017 May 19. doi: 10.1007/s12185-017

5)* Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Ohashi K, Li L, Miyoshi M. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017 Jun;105(6):792-804.

6) Nishida Y, Kimura S, Mizobe H, Yamamichi J, Kojima K, Kawaguchi A, Fujisawa M, Matsue K.  Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. Sci Rep. 2017 Oct 10;7(1):12885.

7) Kimura Y, Takeuchi M, Matsue K. Tubulointerstitial capillaries limited intravascular lymphoma of the kidney. Int J Hematol. 2017 Nov;106(5):589-590